Skip to main content

Table 1 Characteristics of ACS patients stratified by management strategy

From: Impact of provincial and national implementation strategies on P2Y12 inhibitor utilization for acute coronary syndrome in the elderly: an interrupted time series analysis from 2008 to 2018

Characteristic Medical management
n=49,652
PCI
n=56,358
CABG
n=8,132
p value
Age* 75.71 ± 6.50 75.71 ± 6.94 74.11 ± 5.63 <.001
Male sex (%male) 30,742 (61.9%) 35,137 (62.3%) 5973 (73.5%) <.001
Current smoker 6521 (13.1%) 8010 (14.2%) 1272 (15.6%) NS
Previous smoker 17,301 (34.8%) 16,532 (29.3%) 2866 (35.2%) <.001
COPD 5276 (10.6%) 4552 (8.1%) 598 (7.4%) <.001
CVD 5723 (11.5%) 5240 (9.3%) 809 (9.9%) <.001
CHF 7157 (14.4%) 4962 (8.8%) 812 (10.0%) <.001
Diabetes 18,193 (36.6%) 16,737 (29.7%) 2855 (35.1%) <.001
Hyperlipidemia 37,018 (74.6%) 34,964 (62.0%) 5418 (66.6%) <.001
Hypertension 39,566 (79.7%) 40,309 (71.5%) 6025 (74.1%) <.001
History of MI 18,988 (38.2%) 15,950 (28.3%) 1947 (23.9%) <.001
PVD 5583 (11.2%) 4,533 (8.0%) 839 (10.3%) <.001
Renal disease 261 (0.5%) 215 (0.4%) 31 (0.4%) NS
Previous CABG 10,643 (21.4%) 8042 (14.3%) 251 (3.1%) <.001
Previous PCI 11,722 (23.6%) 12,284 (21.8%) 977 (12.0%) <.001
Previous antithrombotic
 Dabigatran 744 (1.5%) 630 (1.1%) 58 (0.1%) <.001
 Apixaban 779 (1.6%) 795 (1.4%) 66 (0.8%) <.001
 Rivaroxaban 992 (2.0%) 1,156 (2.1%) 116 (1.4%) <.001
 Warfarin 4,894 (9.9%) 3,700 (6.6%) 396 (4.9%) <.001
 Prasugrel 21 (0.0%) 36 (0.1%) 0 (0.0%) NS
 Clopidogrel 11,575 (23.3%) 10,614 (18.8%) 1029 (12.7%) <.001
 Ticagrelor 589 (1.2%) 992 (1.8%) 45 (0.6%) <.001
  1. *Mean ± SD
  2. Abbreviations: COPD Chronic obstructive pulmonary disease, CVD Cerebrovascular disease, CHF Congestive heart failure, MI Myocardial infarction, PVD Peripheral vascular disease, CABG Coronary artery bypass grafting surgery, PCI Percutaneous coronary intervention
  3. The baseline characteristics, including medical co-morbidities and previous antithrombotic use, were measured when patient presented with their ACS